Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck

被引:0
|
作者
Haddad, R [1 ]
Posner, M [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
D O I
10.1002/cncr.11194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1589 / 1589
页数:1
相关论文
共 50 条
  • [1] Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck
    Shin, DM
    Glisson, BS
    Khuri, FR
    Lippman, SM
    Ginsberg, L
    Diaz, E
    Papadimitrakopoulou, V
    Feng, L
    Francisco, M
    Garden, A
    Kies, MS
    Myers, J
    Clayman, G
    Hong, WK
    [J]. CANCER, 2002, 95 (02) : 322 - 330
  • [2] Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck - Author reply
    Shin, DM
    [J]. CANCER, 2003, 97 (06) : 1590 - 1590
  • [3] Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
    Bauman, Jessica
    Langer, Corey
    Quon, Harry
    Algazy, Kenneth
    Lin, Alexander
    Desai, Arati
    Mutale, Faith
    Weiss, Jared
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (04) : 1247 - 1253
  • [4] Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Shin, DM
    Khuri, FR
    Glisson, BS
    Ginsberg, L
    Papadimitrakopoulou, VM
    Clayman, G
    Lee, JJ
    Ang, KK
    Lippman, SM
    Hong, WK
    [J]. CANCER, 2001, 91 (07) : 1316 - 1323
  • [5] Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Ready, Neal E.
    Rathore, Ritesh
    Johnson, Tirrell T.
    Nadeem, Ahmed
    Chougule, Prakash
    Ruhl, Charles
    Radie-Keane, Kathy
    Theall, Kathy
    Wanebo, Harold J.
    Marcello, Jennifer
    Kennedy, Teresa
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (01): : 6 - 12
  • [6] Phase II study of biweekly TPFL induction chemotherapy for locally advanced squamous cell carcinoma of head and neck
    Hsieh, C. Y.
    Lein, M. Y.
    Hua, C-H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [7] Preliminary report of phase II study of neoadjuvant chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in locally advanced squamous cell carcinoma of the head and neck cancer (SCCHN) patients
    Chitapanarux, I.
    Lorvidhaya, V.
    Tharavichitkul, E.
    Sittitrai, R.
    Pattarasakulchai, I.
    Kamnerdsupaphon, P.
    Sukthomyal, V.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 311 - 312
  • [8] Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck
    Moosmann, P
    Egli, F
    Stahel, RA
    Jost, L
    [J]. ONKOLOGIE, 2003, 26 (06): : 568 - 572
  • [9] Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck
    Okano, Susumu
    Homma, Akihiro
    Kiyota, Naomi
    Tahara, Makoto
    Hanai, Nobuhiro
    Asakage, Takahiro
    Matsuura, Kazuto
    Ogawa, Takenori
    Saito, Yuki
    Sano, Daisuke
    Kodaira, Takeshi
    Motegi, Atsushi
    Yasuda, Koichi
    Takahashi, Shunji
    Tanaka, Kaoru
    Onoe, Takuma
    Yokota, Tomoya
    Imamura, Yoshinori
    Ariizumi, Yosuke
    Akimoto, Tetsuo
    Hayashi, Ryuichi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (02) : 173 - 179
  • [10] Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
    Tanaka, Ryoko
    Ueki, Yushi
    Ohshima, Shusuke
    Omata, Jo
    Yokoyama, Yusuke
    Takahashi, Takeshi
    Shodo, Ryusuke
    Yamazaki, Keisuke
    Ohtaki, Kohei
    Togashi, Takafumi
    Horii, Arata
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1133 - 1141